Expanded Access Program of Neladalkib (NVL-655) for Patients With Advanced ALK+ NSCLC or Other ALK+ Solid Tumors
NCT ID: NCT06834074
Last Updated: 2026-01-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
AVAILABLE
EXPANDED_ACCESS
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
NCT05384626
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
NCT06765109
Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC
NCT01947608
Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer
NCT04362072
Expanded Access to ABBV-706
NCT07310277
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
NVL-655
Drug: NVL-655
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Histologically or cytologically confirmed locally advanced or metastatic NSCLC or other solid tumors with a documented ALK rearrangement or activating ALK mutation.
3. Previously received at least one ALK TKI (for patients with NSCLC) or any prior therapy (for patients with other solid tumors), with no comparable or satisfactory alternative treatment options, in the opinion of the treating physician.
4. Enrollment in a clinical trial of neladalkib is not possible.
5. Adequate organ function and bone marrow reserve.
Exclusion Criteria
2. Previous surgery, chemotherapy, radiotherapy or other anti-cancer therapy or participation in other studies within timeframe indicated in the protocol.
3. Ongoing anti-cancer therapy.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nuvalent Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Of California Irvine Medical Center
Orange, California, United States
University of Colorado Anschutz School of Medicine
Aurora, Colorado, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Henry Ford Cancer Institute
Detroit, Michigan, United States
Washington University in St. Louis
St Louis, Missouri, United States
NYU Langone Health
New York, New York, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Duke University
Durham, North Carolina, United States
The Ohio State University
Columbus, Ohio, United States
University of Washington / Fred Hutchinson Cancer Center
Seattle, Washington, United States
Royal North Shore Hospital
St Leonards, New South Wales, Australia
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia
Cross Cancer Institute
Edmonton, Alberta, Canada
BC Cancer - Vancouver
Vancouver, British Columbia, Canada
Princess Margaret Hospital
Toronto, Ontario, Canada
Centre Leon Berard
Lyon, Auvergne-Rhône-Alpes, France
GCS IUCT Oncopole
Toulouse, Occitanie, France
CHU de Nantes
Nantes, Pays de la Loire Region, France
Institut Gustave Roussy
Villejuif, Île-de-France Region, France
Stichting Het Nederlands Kanker Instituut
Amsterdam, North Holland, Netherlands
Antoni van Leeuwenhoek Hospital
Amsterdam, , Netherlands
University Medical Center Groningen
Groningen, , Netherlands
National University Hospital Singapore
Singapore, , Singapore
National Cancer Centre Singapore
Singapore, , Singapore
Seoul National University Hospital
Seoul, Jongno-gu, South Korea
Uomi Cancer Center-Clinica Tres Torres
Barcelona, , Spain
Hospital Universitario Vall d'Hebron
Barcelona, , Spain
Hospital Universitario 12 de Octubre
Madrid, , Spain
Kantonsspital Luzern
Lucerne, , Switzerland
Ospedale Italiano di Lugano
Viganello, , Switzerland
National Taiwan University Hospital
Taipei, , Taiwan
The Royal Marsden Hospital
Sutton, Surrey, United Kingdom
The Royal Marsden Hospital
London, UK, United Kingdom
The Christie Hospital
Manchester, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NVL-655-EAP
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.